ReNerve Limited (RNV.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUDTTM unavailable because four recent quarterly reports are not available| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | - | - | - | - | - | - | - | - |
| Operating profit | AUD m | - | |||||||
| Net profit | AUD m | - | - | - | - | - | - | - | - |
| EPS reported | AUD | - | |||||||
| Operating cashflow per share | AUD | - | |||||||
| Capex per share | AUD | - | |||||||
| FCF per share | AUD | - | |||||||
| Free cash flow | AUD m | - | |||||||
| Net debt | AUD m | - | |||||||
| Book value equity | AUD m | - | |||||||
| Book value per share | AUD | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | AUD | - |
Financial summary
Financials in AUDTTM unavailable because four recent quarterly reports are not available| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; and amniotic tissue product ranges used to aid the healing of wounds under the Empliq brand. In addition, it provides Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand that are in development phase. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; and amniotic tissue product ranges used to aid the healing of wounds under the Empliq brand. In addition, it provides Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand that are in development phase. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free